Search

everythinglearnresearchcommunity

for

Search:↓

Concerns about hair loss treatments like finasteride and minoxidil not being administered during a coma. Dutasteride remains in the system longer, and hair loss may not be immediate if treatment stops temporarily.

Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.

Minoxidil is commonly used for male pattern baldness, but Procapil is considered to have fewer side effects and be more effective. The user seeks information or experiences regarding Procapil.

The user transitioned from finasteride to Cyproterone and started using Minoxidil, resulting in healthier hair and regrowth. They plan to wean off Minoxidil in a year, depending on regrowth.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

PP405 shows promise for hair growth with significant results after 4 weeks, but skepticism exists due to its unavailability. Some users are hopeful for its potential, while others express concerns about side effects and market release delays.

Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.

The user is frustrated with their dermatologist's refusal to prescribe oral Minoxidil and Finasteride for hair loss, despite starting Finasteride recently. They consider discussing oral Minoxidil with their primary care doctor and exploring telehealth options.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.

Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

A 19-year-old concerned about long-term effects of 5AR inhibitors on physical appearance. They have used finasteride and plan to try dutasteride or RU58841; responses suggest improved skin, hair, and confidence.

Treatments for hair loss, specifically the use of Spironolactone (Spiro) and oral Minoxidil, as well as Finasteride and RU58841.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.

Latanoprost is discussed as a potential hair loss treatment, noted for its synergy with minoxidil and 5-AR inhibitors, but concerns include its effectiveness on scalp hair, cost, and potential skin darkening. Some users express interest in trying latanoprost or bimatoprost despite limited real-world evidence.

Diffuse hair thinning and treatments like finasteride and minoxidil. Early detection and treatment are crucial for effective management.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

A 35-year-old shared their 5-month hair regrowth progress, using 0.5mg oral finasteride daily, topical minoxidil/finasteride once daily, derma stamping 1-3 times a week, washing hair daily or every other day with peppermint soap, and using eczema lotion for scalp health. Commenters congratulated the individual on the significant improvement in their hairline.

A user shared their one-year hair loss treatment progress using oral finasteride, topical finasteride/minoxidil, and microneedling, reporting no current side effects and significant hair improvement. They also use Head & Shoulders for dandruff control and recommend consistency in treatment.

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

The conversation discusses using a combination of redensyl, capixyl, and procapil (RCP) for hair loss, with some users also mentioning minoxidil and finasteride. Users shared mixed experiences, with some suggesting "RevivHair Max Hair Stimulating Serum" for better results, while others reported no noticeable effects from using products like The Ordinary Multi-Peptide Serum.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

A user shared their 11-year experience with spironolactone and nearly 5 years with finasteride for hair loss, recently adding oral minoxidil and stopping birth control. Various treatments were discussed, including organic options, checking for underlying health issues, considering dutasteride, and the potential role of progesterone in hair loss.

A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.

The user experienced severe scalp itching and hair loss while on dutasteride, which they linked to caffeine and masturbation. They plan to cut out both to see if their hair density improves.

A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.